- Home
- ALL vs MRNA Comparison
ALL vs MRNA Comparison
Compare ALL & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALL | MRNA |
|---|---|---|
| Founded | 1931 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.7B | 61.6B |
| IPO Year | 1996 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ALL | MRNA |
|---|---|---|
| Price | $255.73 | $143.17 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 18 | 12 |
| Target Price | ★ $226.65 | $34.27 |
| AVG Volume (30 Days) | 1.4M | ★ 31.1M |
| Earning Date | 04-29-2026 | 05-01-2026 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | ★ 124.01 | 21.77 |
| EPS | ★ 21.73 | N/A |
| Revenue | ★ $67,685,000,000.00 | $19,263,000,000.00 |
| Revenue This Year | N/A | $9.36 |
| Revenue Next Year | $5.96 | $15.43 |
| P/E Ratio | $11.84 | ★ N/A |
| Revenue Growth | ★ 5.58 | 4.29 |
| 52 Week Low | $188.08 | $22.28 |
| 52 Week High | $277.22 | $176.66 |
Technical Indicators
Market Signals| Indicator | ALL | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 49.79 | 60.82 |
| Support Level | $254.46 | $46.85 |
| Resistance Level | $257.67 | $156.42 |
| Average True Range (ATR) | 4.41 | 9.82 |
| MACD | -0.54 | -2.66 |
| Stochastic Oscillator | 44.42 | 51.43 |
Price Performance
Historical ComparisonAbout ALL Allstate Corporation (The)
Allstate is one of the largest US property-casualty insurers in the US. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 6,000 exclusive agents.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.